Table 1.
Clinical Characteristics of 81 Patients with Glioma
| Patient Characteristics (N=81) | Number (%) |
|---|---|
| Gender, n (%) | |
| Male | 59 (72.84%) |
| Female | 22 (27.16%) |
| Age(year), y (range) | |
| Median | 46 |
| Range | 5–75 |
| ≤40 | 29 (35.80%) |
| >40 | 52 (64.20%) |
| Tumor characteristics (N=83) | |
| WHO, n (%) | |
| I | 6 (7.23%) |
| II | 21 (25.30%) |
| III | 15 (18.07%) |
| IV | 41 (49.40%) |
| Pathology, n (%) | |
| PA | 5 (6.02%) |
| A | 10 (12.05%) |
| O | 11 (13.25%) |
| AA | 10 (12.05%) |
| AO | 6 (7.23%) |
| GBM | 32 (38.55%) |
| DMG | 8 (9.64%) |
| Other | 1 (1.20%) |
| Disease status, n (%) | |
| Primary | 12 (14.46%) |
| Recurrent | 71 (85.54%) |
| MGMT methylation, n (%) | |
| Positive | 43 (51.81%) |
| Negative | 39 (46.99%) |
| NA | 1 (1.20%) |
| 1p/19q codeletion | |
| Positive | 10 (12.05%) |
| Negative | 72 (86.75%) |
| NA | 1 (1.20%) |
Note: Oligodendrogliomas were identified by their oligodendrocyte components.
Abbreviations: PA, pilocytic astrocytoma (WHO grade I); A, astrocytoma (WHO grade II); O, oligodendroglioma (WHO grade II); AA, anaplastic astrocytoma (WHO grade III); AO, anaplastic oligodendroglioma (WHO grade III); GBM, glioblastoma multiforme (WHO grade IV); DMG, diffuse midline glioma.